Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Farma ondernemingen’

Novartis launches first large-scale smartphone-based study in multiple sclerosis

Novartis has launched what it claims is the first large-scale mobile research study which will gather data on multiple sclerosis (MS) from patients via their smartphones, removing the need for them to visit a medical professional at the clinic.

Bron: Pharmafile Meer lezen »

Hikma risks a stratospheric 430% price increase on product

It wasn’t so long ago that pharmaceutical companies could change the prices of its products with little scrutiny. A series of price gauging stories has put an end to that era and now companies are under much more pressure to be both transparent over their price increases, with more now committing to ensuring they keep […]

Bron: Pharmafile Meer lezen »

Topas Therapeutics inks research agreement with Eli Lilly on immune tolerance

Topas Therapeutics GmbH, a Hamburg, Germany─based private company, has announced that it has signed a multi─year agreement with Eli Lilly and Company (Lilly) to collaborate in the field of antigen─specific tolerance.

Bron: Pharma Biz Meer lezen »

J&J ordered to pay $417 million in trial over talc cancer risks

Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company’s talc-based products like Johnson’s Baby Powder for feminine hygiene.

Bron: Reuters Meer lezen »

AstraZeneca strikes mRNA-based partnership in respiratory disease

AstraZeneca and MedImmune, the company’s biologics research arm, have forged a five year research partnership with mRNA-based pulmonary disease specialist Ethris to leverage the latter’s proprietary SNIM RNA technology in the development of stabilised non-immunogenic modified RNA therapies for respiratory diseases.

Bron: Pharmafile Meer lezen »

Medivir begins phase I/II study of birinapant in combo with Keytruda in patients with treatment-refractory solid tumours

Medivir AB has announces that the first patient has been enrolled in the company’s phase I/II study of birinapant in combination with the anti─PD─1 therapy Keytruda (pembrolizumab), which is marketed by MSD

Bron: Pharma Biz Meer lezen »

FDA Approves New Indication, Formulation for Lynparza

The approvals were based on two, placebo-controlled trials (SOLO-2, Study 19) in patients with recurrent ovarian cancers who were in response to platinum-based therapy.

Bron: Monthly Prescribing Reference (MPR): Drug News Meer lezen »

Novartis begins ‘next-generation’ malaria treatment trial

Novartis, alongside Medicines for Malaria Venture (MMV), have revealed that trials into a new antimalarial compound have begun in a first clinic in Mali. The trial is investigating a compound, KAF156, as a potentially ground-breaking treatment that can clear malaria infection, including particularly resistant strains, and block the transmission of the malaria parasite.  

Bron: Pharmafile Meer lezen »

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers’ blood thinner Xarelto led to severe internal bleeding.

Bron: Reuters Meer lezen »

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Novo Nordisk says its once-weekly GLP-1 agonist semaglutide could become a “new standard” in type 2 diabetes after beating rival Eli Lilly’s Trulicity (dulaglutide) in a phase III trial. Analysts predict the drug could be worth $8.7bn in the next five years.

Bron: PMLiVE Meer lezen »

« Oudere artikelen |